Narrow search
Showing 1 - 10 of 76,764
Cover Image
Chapter Twelve. Markets for Pharmaceutical Products
Scott Morton, Fiona; Kyle, Margaret - In: Handbook of health economics : volume 2, (pp. 763-823). 2011
This chapter describes the market for pharmaceuticals, which exceeded $500 million in sales in 2010. The industry is …
Persistent link: https://www.econbiz.de/10014025576
Cover Image
The effect of regulated competition on pharmaceutical advertising and promotion
David, Guy; Markowitz, Sara - In: Eastern economic journal 41 (2015) 1, pp. 24-39
Persistent link: https://www.econbiz.de/10010489493
Cover Image
Pharmaceutical patents : incentives for R&D or marketing?
Brekke, Kurt R. (contributor); Straume, Odd Rune (contributor) - 2008
We analyse how a patent-holding pharmaceutical firm may strategically use advertising of existing drugs to affect R … industry. Within a fairly general model framework, we derive exact conditions for advertising and R&D being substitute … strategies for the incumbent firm and show that it may overinvest in advertising to reduce the incentive for an entrant to invest …
Persistent link: https://www.econbiz.de/10003771873
Cover Image
Pharmaceutical patents: incentives for research and development or marketing?
Brekke, Kurt R.; Straume, Odd Rune - In: Southern economic journal 76 (2009) 2, pp. 351-374
Persistent link: https://www.econbiz.de/10003903146
Cover Image
Marketing, Product Differentiation and Competition in the Market for Antiulcer Drugs
King, Charles - 2014
This paper investigates one of the largest pharmaceutical markets using a discrete choice model that allows marketing to affect product differentiation. Four main results emerge from an analysis of monthly panel data on antiulcer drugs from 1977 to 1993. Observed drug characteristics became less...
Persistent link: https://www.econbiz.de/10012709821
Cover Image
Drug Pricing in a Regulated Market
Capri, Stefano; Levaggi, Rosella - 2004
In this article we analyse the problem of determining the price for new drugs in a market where a stringent budget constraint on public expenditure exists and we suggest an innovative methodology to set their prices. The market is characterised by asymmetry of information and a high proportion...
Persistent link: https://www.econbiz.de/10014071880
Cover Image
Pharmaceutical Patents : Incentives for R&D or Marketing?
Brekke, Kurt Richard; Straume, Odd Rune - 2021
We analyse how a patent-holding pharmaceutical firm may strategically use advertising of existing drugs to affect R … industry. Within a fairly general model framework, we derive exact conditions for advertising and R&D being substitute … strategies for the incumbent firm and show that it may overinvest in advertising to reduce the incentive for an entrant to invest …
Persistent link: https://www.econbiz.de/10013316463
Cover Image
Entry into New Pharmaceutical Submarkets : The Role of Submarket Concentration
Amisano, Gianni - 2014
Using a reduced form binary econometric model, we analyze the determinants of pharmaceutical companies entry decisions into new submarkets. Our sample includes data for pharmaceutical companies over the period 1987-1998 for seven countries. Estimation is done both at the aggregate level and at a...
Persistent link: https://www.econbiz.de/10012708979
Cover Image
Advertising regulations in pharmaceutical markets : product versus enlightenment
Ishida, Junichiro; Takahara, Tsuyoshi - 2019
This paper analyzes the optimal content regulation of direct-to-consumer advertisement (DTCA) in a pharmaceutical market, with particular focus on the distinction between product and enlightenment advertisement. Firms are allowed to freely promote their own specific products under product DTCA,...
Persistent link: https://www.econbiz.de/10012024745
Cover Image
The Effect of Price Caps on Pharmaceutical Advertising : Evidence from the 340b Drug Pricing Program
Hristakeva, Sylvia; Mortimer, Julie Holland; Yde, Eric - National Bureau of Economic Research - 2024
We study the effect of price caps on the provision of costly effort by pharmaceutical firms using variation in drug discounts generated by a price regulation program that allows eligible hospitals to purchase outpatient drugs at steep discounts. These discounts directly affect drug...
Persistent link: https://www.econbiz.de/10014512103